日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Transformable Tumor Microenvironment-Responsive Oxygen Vacancy-Rich MnO(2)@Hydroxyapatite Nanospheres for Highly Efficient Cancer Sonodynamic Immunotherapy

可转化肿瘤微环境响应的富氧空位MnO(2)@羟基磷灰石纳米球用于高效癌症声动力免疫疗法

Li, Minxing; Liu, Qiyu; Xie, Songzuo; Weng, Desheng; He, Jinjun; Yang, Xinyi; Liu, Yuanyuan; You, Jinqi; Liao, Jinghao; Wang, Peng; Lu, Xihong; Zhao, Jingjing

The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers.

CXCL10-CXCR3轴诱导肿瘤相关中性粒细胞干扰CTL介导的EBV相关上皮癌的抗肿瘤活性。

Ouyang Dijun, Xiang Tong, Chen Yuanyuan, Song Mengjia, Zhao Jingjing, Chen Hao, Li Si, Zhang Lifeng, Xu Chi, Ren Yan, Tao Yong, Wang Qijing, He Jia, Li Yongqiang, Xie Sisi, Liu Yuanyuan, Wang Yan, Yang Xinyi, You Jinqi, Xie Songzuo, Li Yingzi, Weng Desheng, Pan Qiuzhong, Yang Qi, Xia Jianchuan

Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population

舒鲁法替尼治疗神经内分泌肿瘤患者的疗效和安全性:一项中国人群真实世界研究

Liu, Yuanyuan; Yang, Xinyi; Wang, Yan; Xie, Songzuo; Li, Minxing; You, Jinqi; Tang, Yan; Zhao, Jingjing; Weng, Desheng

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

安罗替尼作为一线化疗后晚期软组织肉瘤的维持治疗(ALTER-S006):一项多中心、开放标签、单臂 II 期试验

Xu, Bushu; Pan, Qiuzhong; Pan, Hua; Li, Haomiao; Li, Xianan; Chen, Jing; Pang, Danmei; Zhang, Baoqing; Weng, Desheng; Peng, Ruiqing; Fang, Meiyu; Zhang, Xing

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype

CircITGB6通过将肿瘤相关巨噬细胞极化重置为M2表型,促进卵巢癌对顺铂的耐药性。

Li, Han; Luo, Fan; Jiang, Xingyu; Zhang, Weijing; Xiang, Tong; Pan, Qiuzhong; Cai, Liming; Zhao, Jingjing; Weng, Desheng; Li, Yue; Dai, Yuhu; Sun, Fengze; Yang, Chaopin; Huang, Yue; Yang, Jieying; Tang, Yan; Han, Yulong; He, Mian; Zhang, Yanna; Song, Libing; Xia, Jian-Chuan

CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma

CMTM6通过阻止肝细胞癌中p21的泛素化来抑制肿瘤生长并逆转化疗耐药性。

Huang, Yue; Zhu, Yingqin; Yang, Jieying; Pan, Qiuzhong; Zhao, Jingjing; Song, Mengjia; Yang, Chaopin; Han, Yulong; Tang, Yan; Wang, Qijing; He, Jia; Li, Yongqiang; He, Junyi; Chen, Hao; Weng, Desheng; Xiang, Tong; Xia, Jian Chuan

Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma

新辅助帕唑帕尼或阿昔替尼联合程序性死亡蛋白-1激活的树突状细胞-细胞因子诱导的杀伤细胞免疫疗法可能有助于肾细胞癌患者的手术。

Zhang, Zhiling; Xiong, Longbin; Wu, Zeshen; Liu, Huiming; Ning, Kang; Peng, Yulu; Yu, Chunping; Ding, Ya; Weng, Desheng; Xia, Jianchuan; Jiang, Lijuan; Guo, Shengjie; Han, Hui; Zhou, Fangjian; Dong, Pei

Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer

非小细胞肺癌患者接受PD-L1特异性CAR-T细胞治疗后出现严重的迟发性肺毒性

Liu, Heping; Ma, Yuxiang; Yang, Chaopin; Xia, Shangzhou; Pan, Qiuzhong; Zhao, Hongyun; Fang, Wenfeng; Chen, Xi; Zhang, Yang; Zou, Benyan; Li, Qiuyuan; Wan, Yang; Chen, Hao; Tang, Yan; Zhao, Jingjing; Weng, Desheng; Xia, Liming; Zhang, Li; Xia, Jianchuan

Genotoxic stress induces Sca-1-expressing metastatic mammary cancer cells

基因毒性应激诱导表达Sca-1的转移性乳腺癌细胞

Gong, Jianlin; Lang, Benjamin J; Weng, Desheng; Eguchi, Takanori; Murshid, Ayesha; Borges, Thiago J; Doshi, Sachin; Song, Baizheng; Stevenson, Mary A; Calderwood, Stuart K

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure

伊马替尼治疗失败后,舒尼替尼治疗晚期隆突性皮肤纤维肉瘤取得了良好的疗效。

Xiao, Wei; Que, Yi; Peng, Ruiqing; Ding, Ya; Zhao, Jingjing; Wen, Xizhi; Weng, Desheng; Zhang, Xiaoshi; Guan, Yuanxiang; Zhang, Xing